Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 ... therapeutic market research report of 68 pages with ... business intelligence library. The report "Pemphigus - Pipeline ... the therapeutic development for Pemphigus , complete ... by drug target, mechanism of action (MoA), route ...
(Date:3/31/2015)... KENNEBUNK, Maine , March 31, 2015 /PRNewswire/ ... aggregated enrollment in Medicare Advantage (MA) plans in ... approximately 17.3 million people were enrolled in Medicare ... of more than 1.3 million members year-over-year.  54.3 ... the Centers for Medicare and Medicaid Services (CMS), ...
(Date:3/31/2015)... TUCSON, Ariz. , March 31, 2015  SynCardia ... Investigational Device Exemption (IDE) clinical study on the effective ... The ... with as many as 30 heart failure patients. Patients ... Total Artificial Heart as a bridge to a donor ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... BRIGHTON, Mich., March 15, 2012 LifeSecure Insurance ... one-stop online shop where caregivers can access quality home ... needs of loved ones. LifeSecure,s Caregiver,s ... daily living aids and home modification tools to medical ...
... 15, 2012 Heptares Therapeutics, the leading GPCR ... Kenny, will present overview of the Company at 09:45am CET ... Annual BIO-Europe Spring international partnering conference. The presentation will take ... which is produced by EBD Group, is taking place at ...
Cached Medicine Technology:LifeSecure Opens Online Caregiver's Marketplace 2Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012 2
(Date:4/1/2015)... Enterprise Integration has appeared on ... distinguished list and report identifying the world’s top ... list is currently available on the MSPmentor. Additional ... MSPs in North America ,     The top ...     The top MSPs in Asia, Australia and ...
(Date:3/31/2015)... Bon Secours New York Health System ... Nursing Care Center family last week. The Sisters formerly ... Yonkers which is scheduled to close later this year. ... the Sisters of Charity of New York, the decision ... place their Sisters at Schervier Nursing Care Center followed ...
(Date:3/31/2015)... On November 24, 2014, Per Wickstrom had an opportunity ... problem of substance abuse and the solutions that are offered ... and recovery, gives a unique first-person perspective on addiction and ... the New York Giants, Taylor’s early career was almost cut ... he was able to straighten out long enough to make ...
(Date:3/31/2015)... 31, 2015 Over the last several ... technique have yielded better results and more efficient ... and perfected by a good hair transplant surgeon, has ... techniques of hair restoration have improved the efficiency of ... used to add precision and flexibility to the field ...
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration has ... of using beard hair to fill in balding areas ... has now become an absolute option for giving patients the best ... believe that beard to scalp hair transplant can be a patients ... as dense as we would like it,” says Dr. Parsa Mohebi. ...
Breaking Medicine News(10 mins):Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Lawrence Taylor & Per Wickstrom Discuss the Drug Rehabilitation & Recovery Process 2Health News:Beverly Hills Hair Transplant Surgeon Now Combines Advanced Robotic Hair Transplantation and Manual Techniques for Greatest Results 2Health News:Is Beard to Scalp Hair Transplant the Future? 2
... researchers have found that Diethanolamine (DEA), an ingredient found ... to interfere with normal brain development in baby mice. ... mice and seemed to have an adverse effect on ... Professor of nutrition in UNC's schools of public health ...
... a tumor suppressor gene which was identified by Professor Sir ... done on this gene using the mice model shows that ... ageing process. Larry Donehower of Baylor College of Medicine in ... they later developed cancer. In another set he modified the ...
... the fatty acid ratio found in the typical Western diet ... of omega-6 fatty acids// may reduce prostate cancer tumor growth ... issue of the journal Clinical Cancer Research, this initial animal-model ... of diet on lowering an inflammatory response known to promote ...
... Evaluation of bone healing can be primarily dome ... formatting as the primary imaging// technique, according to ... University of Vienna in Vienna, Austria. ... fusion) or spinal fusions who'd undergone MDCT and ...
... the Earth Institute, Columbia University, a well-known economist feels ... Schemes// in order to provide better healthcare facilities for ... Mission, India should make a National Health Insurance scheme ... population of the country still living in poverty" he ...
... Farma, the country's biggest vaccine producer, has been awarded a ... Indonesian government.// ,The Agricultural Ministry awarded the ... billion rupiah (US$1.01 million) was the lowest among the bidding ... from China, which could begin within two weeks after the ...
Cached Medicine News:Health News:Altering Fatty Acid Levels in Diet May Reduce Prostate Cancer Growth Rate 2
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... either EDTA K2 or EDTA K3 ... and therefore blocks the coagulation cascade. ... EDTA anticoagulated blood sample are stable ... tubes are for the examination of ...
Glass Whole Blood Tube with K3EDTA...
Medicine Products: